Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Coen

Showing results (191-200 of 210) with videos related to

Pageof 21
Sort By:
Clinical Pharmacokinetics|October 28, 2024
Changes in Plasma Clearance of CYP450 Probe Drugs May Not be Specific for Altered In Vivo Enzyme Activity Under (Patho)Physiological Conditions: How to Interpret Findings of Probe Cocktail StudiesLaura M de Jong, Marinda van de Kreeke, Mariam Ahmadi, et al.
Mineral and Electrolyte Metabolism|January 1, 1983
1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration aloneG Coen, M Taccone Gallucci, E Bonucci, et al.
Antimicrobial Agents and Chemotherapy|September 3, 2025
Colistin resistance dynamics in <i>Pseudomonas aeruginosa</i> under biofilm and planktonic growthAngie C Alarcon Rios, Laura B Zwep, Bastienne Vriesendorp, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2022
A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variablesYu Fu, Hadi Taghvafard, Medhat M Said, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 4, 2025
Model-based optimisation for teicoplanin dosing in patients undergoing maintenance haemodialysisSebastian T Tandar, Arnaud De Clercq, Linda B S Aulin, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 12, 2018
Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimensAurelia H M de Vries Schultink, Annelies H Boekhout, Jourik A Gietema, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 22, 2017
Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjectsNatalicia de Jesus Antunes, Sven C van Dijkman, Vera Lucia Lanchote, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 27, 2021
Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolismMichael Poppe, Christian Clodi, Christoph Schriefl, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2024
Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteersMaria Sanz-Codina, Wisse van Os, Anh Duc Pham, et al.
British Journal of Clinical Pharmacology|November 14, 2014
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662Huixin Yu, Neeltje Steeghs, Jacqueline S L Kloth, et al.
Pageof 21

Showing results (191-200 of 210) with videos related to

Sort By:
Pageof 21
Clinical Pharmacokinetics|October 28, 2024
Changes in Plasma Clearance of CYP450 Probe Drugs May Not be Specific for Altered In Vivo Enzyme Activity Under (Patho)Physiological Conditions: How to Interpret Findings of Probe Cocktail StudiesLaura M de Jong, Marinda van de Kreeke, Mariam Ahmadi, et al.
Mineral and Electrolyte Metabolism|January 1, 1983
1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration aloneG Coen, M Taccone Gallucci, E Bonucci, et al.
Antimicrobial Agents and Chemotherapy|September 3, 2025
Colistin resistance dynamics in <i>Pseudomonas aeruginosa</i> under biofilm and planktonic growthAngie C Alarcon Rios, Laura B Zwep, Bastienne Vriesendorp, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2022
A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variablesYu Fu, Hadi Taghvafard, Medhat M Said, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 4, 2025
Model-based optimisation for teicoplanin dosing in patients undergoing maintenance haemodialysisSebastian T Tandar, Arnaud De Clercq, Linda B S Aulin, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 12, 2018
Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimensAurelia H M de Vries Schultink, Annelies H Boekhout, Jourik A Gietema, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 22, 2017
Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjectsNatalicia de Jesus Antunes, Sven C van Dijkman, Vera Lucia Lanchote, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 27, 2021
Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolismMichael Poppe, Christian Clodi, Christoph Schriefl, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2024
Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteersMaria Sanz-Codina, Wisse van Os, Anh Duc Pham, et al.
British Journal of Clinical Pharmacology|November 14, 2014
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662Huixin Yu, Neeltje Steeghs, Jacqueline S L Kloth, et al.
Pageof 21